Could a common Blood-Flow drug tame rheumatoid arthritis?
NCT ID NCT06998628
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests whether adding pentoxifylline (a drug usually used for blood flow) to standard methotrexate therapy can reduce inflammation in people with active rheumatoid arthritis. Fifty adults aged 18–70 with moderate-to-severe disease will receive the combination for a set period. The main goal is to see if their disease activity score (DAS28) improves.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pentoxifylline (a blood-flow medication) added to standard methotrexate therapy
What this could lead to
If it works, this could point toward a new, affordable add-on treatment to better control rheumatoid arthritis inflammation.
What could go wrong
This is a small, early Phase 2 trial with only 50 participants. Pentoxifylline is not a proven arthritis drug, and results may not lead to a new standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faculty of Medicine, Al-Azhar University
RECRUITINGDamietta, Damietta Governorate, 34511, Egypt
Contact Phone: •••-•••-•••• Email: •••••@•••••